Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

NCT01777763 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Fungal Infections

Interventions

DRUG: Posaconazole 200 mg
DRUG: Posaconazole 300 mg

Sponsor

Merck Sharp & Dohme LLC